In short
Clinical trials are investigating ACARBOSE in people with obesity. This article explains what the study tested, who took part, and what outcomes were measured, such as tolerability during dose-escalation and symptom scores. The trial compared ACARBOSE-related treatment strategies with other obesity treatments.
Key points
- Only one clinical trial was provided for ACARBOSE. It was a completed Phase 2 interventional study in people with obesity. The study focused on tolerability during dose-escalation, which means checking how well the treatment plan was accepted as the dose increased. The main comparison was between two treatment combinations, and the primary outcome used the total GITE1 score. A total of 39 people were enrolled in the trial.
Trial overview
The provided data includes one clinical trial of ACARBOSE: 2024-520122-11-00, called “A PilOt dose-escalation trial with EMP16 in preparation for Phase III – the POEM trial.”
This was a Phase 2 interventional study and it was marked as Completed.
The trial studied people with obesity.
Study design and treatment comparison
The brief summary says the study was designed to compare the combination of EMP16 plus Vi-Siblin® S with the combination of conventional orlistat plus placebo dietary fibre supplementation during dose-escalation.
The interventions listed in the source include ACARBOSE, ORLISTAT, Vi-Siblin S granulat, alli 60 mg hard capsules, dietary fibre supplement, and a placebo made of maltodextrin.
A placebo is a look-alike treatment used for comparison, and it does not contain the active study treatment.
Who participated
The trial enrolled 39 participants.
The source does not give more detail about age, sex, or other entry rules, so the available information only shows that the target population was people with obesity.
What the trial measured
The primary outcome was the difference in total GITE1 score between EMP16 combined with Vi-Siblin® S and conventional orlistat combined with placebo dietary fibre supplement.
This means the researchers were comparing how the two treatment approaches were tolerated during dose increases.
Dose-escalation means the amount of treatment is increased step by step, so researchers can watch how people respond as the dose changes.
What the trial results mean for patients
From the data provided, this ACARBOSE-related trial was not designed to prove long-term benefit in obesity, but to study tolerability in a controlled research setting.
Because the study was completed, the planned testing phase has ended, but the source does not provide the final results or whether the treatment strategy moved forward to later studies.
For patients, the key point is that ACARBOSE appears in a trial focused on obesity research, where the main question was how well the treatment plan could be used during dose increases.